Professor Dale Gerding is an expert on therapy for C.difficile whose work was recently recognised with a Lifetime Achievement award from the C Diff Foundation. Over the course of a detailed interview with Dr Andy Smith (analyst and microbiologist), Professor Gerding shares his latest thoughts on the growing threat posed by C diff. He also discusses the merits in its treatment shown by NTCD-M3, being developed by Destiny Pharma where Dale is a member of the Scientific Advisory Board.